167 related articles for article (PubMed ID: 33452448)
1. Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial.
Pettengell R; Uddin R; Boumendil A; Johnson R; Metzner B; Martín A; Romejko-Jarosinska J; Bence-Bruckler I; Giri P; Niemann CU; Robinson SP; Kimby E; Schmitz N; Dreger P; Goldstone AH; Montoto S
Bone Marrow Transplant; 2021 Jun; 56(6):1413-1421. PubMed ID: 33452448
[TBL] [Abstract][Full Text] [Related]
2. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era.
Sesques P; Bourcier J; Golfier C; Lebras L; Nicolas-Virelizier E; Hacini M; Perrin MC; Voillat L; Bachy E; Traverse-Glehen A; Moreau A; Martin L; Ramla S; Casasnovas O; Le Gouill S; Salles G; Ghesquières H
Hematol Oncol; 2020 Apr; 38(2):137-145. PubMed ID: 31953963
[TBL] [Abstract][Full Text] [Related]
4. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation.
Pettengell R; Schmitz N; Gisselbrecht C; Smith G; Patton WN; Metzner B; Caballero D; Tilly H; Walewski JA; Bence-Bruckler I; To B; Geisler CH; Schots R; Kimby E; Taverna CJ; Kozák T; Dreger P; Uddin R; Ruiz de Elvira C; Goldstone AH
J Clin Oncol; 2013 May; 31(13):1624-30. PubMed ID: 23547078
[TBL] [Abstract][Full Text] [Related]
5. Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience.
Bourcier J; Gastinne T; Leux C; Moreau A; Bossard C; Mahé B; Blin N; Dubruille V; Touzeau C; Voldoire M; Guillaume T; Peterlin P; Gallas P; Garnier A; Maisonneuve H; Moreau P; Juge-Morineau N; Jardel H; Chevallier P; Moreau P; Le Gouill S
Ann Hematol; 2016 Aug; 95(8):1287-93. PubMed ID: 27297970
[TBL] [Abstract][Full Text] [Related]
6. Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score.
Peters AC; Duan Q; Russell JA; Duggan P; Owen C; Stewart DA
Leuk Lymphoma; 2011 Nov; 52(11):2124-9. PubMed ID: 21740097
[TBL] [Abstract][Full Text] [Related]
7. Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party.
Bento L; Boumendil A; Finel H; Le Gouill S; Amorim S; Monjanel H; Bouabdallah R; Bay JO; Nicolas-Virelizier E; McQuaker G; Rossi G; Johnson R; Huynh A; Ceballos P; Rambaldi A; Bachy E; Malladi R; Orchard K; Pohlreich D; Tilly H; Bonifazi F; Poiré X; Guilhot F; Haenel A; Crawley C; Metzner B; Gribben J; Russell NH; Damaj G; Thomson K; Dreger P; Montoto S
Bone Marrow Transplant; 2017 Aug; 52(8):1120-1125. PubMed ID: 28530668
[TBL] [Abstract][Full Text] [Related]
8. Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure.
Jiménez-Ubieto A; Grande C; Caballero D; Yáñez L; Novelli S; Hernández-Garcia MT; Manzanares M; Arranz R; Ferreiro JJ; Bobillo S; Mercadal S; Galeo A; López Jiménez J; Moraleda JM; Vallejo C; Albo C; Pérez E; Marrero C; Magnano L; Palomera L; Jarque I; Martínez-Sánchez P; Martín A; Coria E; López-Guillermo A; Salar A; Lahuerta JJ
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1631-1640. PubMed ID: 28533060
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up demonstrates curative potential of autologous stem cell transplantation for relapsed follicular lymphoma.
Puckrin R; Chua N; Chin K; Peters A; Duggan P; Shafey M; Storek J; Jamani K; Owen C; Stewart D
Br J Haematol; 2023 Apr; 201(2):319-325. PubMed ID: 36625160
[TBL] [Abstract][Full Text] [Related]
10. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma.
Sabloff M; Atkins HL; Bence-Bruckler I; Bredeson C; Fergusson D; Genest P; Hopkins H; Hutton B; Mcdiarmid S; Huebsch LB
Biol Blood Marrow Transplant; 2007 Aug; 13(8):956-64. PubMed ID: 17640600
[TBL] [Abstract][Full Text] [Related]
11. Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial.
Ladetto M; Tavarozzi R; Zanni M; Evangelista A; Ferrero S; Tucci A; Botto B; Bolis S; Volpetti S; Zilioli VR; Puccini B; Arcari A; Pavone V; Gaidano G; Corradini P; Tani M; Cavallo F; Milone G; Ghiggi C; Pinto A; Pastore D; Ferreri AJM; Latte G; Patti C; Re F; Benedetti F; Luminari S; Pennese E; Bossi E; Boccomini C; Anastasia A; Bottelli C; Ciccone G; Vitolo U
Ann Oncol; 2024 Jan; 35(1):118-129. PubMed ID: 37922989
[TBL] [Abstract][Full Text] [Related]
12. Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity.
Phipps C; Gopal AK; Storer BE; Cassaday RD; Press OW; Till BG; Pagel JM; Palanca-Wessels MC; Philip M; Bensinger WI; Holmberg LA; Shustov AR; Green DJ; Chauncey T; Maloney DG; Libby EN
Leuk Lymphoma; 2015 Jan; 56(1):92-6. PubMed ID: 24707941
[TBL] [Abstract][Full Text] [Related]
13. Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era.
Hunter BD; Herr M; Meacham PJ; Barlaskar F; Evans AG; Burack WR; Liesveld JL; Becker MW; Milner LA; Constine LS; Dhakal S; Barr PM; Friedberg JW; Casulo C
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):145-151. PubMed ID: 27998707
[TBL] [Abstract][Full Text] [Related]
14. The impact of total body irradiation on the outcome of patients with follicular lymphoma treated with autologous stem-cell transplantation in the modern era: a retrospective study of the EBMT Lymphoma Working Party.
El-Najjar I; Boumendil A; Luan JJ; Bouabdallah R; Thomson K; Mohty M; Colombat P; Biron P; Tilly H; Pfreundschuh M; Cordonnier C; Sureda A; Cahn JY; Vernant JP; Gribben J; Cook G; Haynes AP; Ferrant A; Finel H; Montoto S; Dreger P;
Ann Oncol; 2014 Nov; 25(11):2224-2229. PubMed ID: 25193988
[TBL] [Abstract][Full Text] [Related]
15. Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party-EBMT.
Bento L; Boumendil A; Finel H; Khvedelidze I; Blaise D; Fegueux N; Castagna L; Forcade E; Chevallier P; Mordini N; Brice P; Deconinck E; Gramatzki M; Corradini P; Hunault M; Musso M; Tsoulkani A; Caballero D; Nati S; Montoto S; Sureda A;
Bone Marrow Transplant; 2021 Mar; 56(3):655-663. PubMed ID: 33046830
[TBL] [Abstract][Full Text] [Related]
16. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study.
Brugger W; Hirsch J; Grünebach F; Repp R; Brossart P; Vogel W; Kopp HG; Manz MG; Bitzer M; Schlimok G; Kaufmann M; Ganser A; Fehnle K; Gramatzki M; Kanz L
Ann Oncol; 2004 Nov; 15(11):1691-8. PubMed ID: 15520073
[TBL] [Abstract][Full Text] [Related]
17. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.
Kolstad A; Pedersen LB; Eskelund CW; Husby S; Grønbæk K; Jerkeman M; Laurell A; Räty R; Elonen E; Andersen NS; Brown PD; Kimby E; Bentzen H; Sundström C; Ehinger M; Karjalainen-Lindsberg ML; Delabie J; Ralfkiær E; Fagerli UM; Nilsson-Ehle H; Lauritzsen GF; Kuittinen O; Niemann C; Geisler CH;
Biol Blood Marrow Transplant; 2017 Mar; 23(3):428-435. PubMed ID: 28039078
[TBL] [Abstract][Full Text] [Related]
18. Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma.
Nademanee A; Molina A; Dagis A; Snyder DS; O'Donnell MR; Parker P; Stein A; Smith E; Planas I; Kashyap A; Spielberger R; Fung H; Krishnan A; Bhatia R; Wong KK; Somlo G; Margolin K; Chow W; Sniecinski I; Vora N; Slovak M; Niland JC; Forman SJ
Clin Lymphoma; 2000 Jun; 1(1):46-54. PubMed ID: 11707813
[TBL] [Abstract][Full Text] [Related]
19. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis.
Mangel J; Leitch HA; Connors JM; Buckstein R; Imrie K; Spaner D; Crump M; Pennell N; Boudreau A; Berinstein NL
Ann Oncol; 2004 Feb; 15(2):283-90. PubMed ID: 14760123
[TBL] [Abstract][Full Text] [Related]
20. Prolonged clinical remissions in patients with relapsed or refractory follicular lymphoma treated with autologous stem cell transplantation incorporating rituximab.
Berinstein NL; Bhella S; Pennell NM; Cheung MC; Imrie KR; Spaner DE; Milliken V; Zhang L; Hewitt K; Boudreau A; Reis MD; Chesney A; Good D; Ghorab Z; Hicks LK; Piliotis E; Buckstein R
Ann Hematol; 2015 May; 94(5):813-23. PubMed ID: 25567231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]